Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Arteriovenous fistula Stories

2014-04-16 16:30:13

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: U.S. Market for Dialysis Equipment and Concentrateshttp://www.reportbuyer.com/pharma_healthcare/medical_devices/u_s_market_dialysis_equipment_concentrates.html Abstract:The total dialysis device and concentrates market will grow to a value of almost $2 billion over the forecast period. The total dialysis device and concentrates market includes the markets for hemodialysis machines,...

2013-10-31 00:20:39

SALT LAKE CITY, Oct. 30, 2013 /PRNewswire/ -- Vital Access Corporation today announced that on Friday, October 25(th), Dr. John Ross, MD, FACS performed live VWING Vascular Needle Guide implantation cases and Dr. William Jennings, MD, FACS presented clinical data from the pivotal U.S. SAVE study at the 2013 Controversies in Dialysis Access (CiDA) Meeting in San Francisco. As part of the CiDA conference agenda, Dr. John Ross performed three VWING implantation cases at his surgical...

2013-10-21 20:22:00

Principal Investigator Dr. Jennings to discuss study results and VWING surgical technique SALT LAKE CITY, Oct. 21, 2013 /PRNewswire/ -- Vital Access Corporation today announced that Dr. William Jennings will present results from the recently completed U.S. SAVE study, an IDE pivotal trial of the VWING(TM) Vascular Needle Guide, at the 2013 CIDA Meeting in San Francisco. Dr. Jennings, who was a principal investigator for the SAVE study at the St. John Medical Center in Tulsa, is...

2013-10-09 16:23:34

Clinical study will investigate benefits of VWING for self-cannulation SALT LAKE CITY, Oct. 9, 2013 /PRNewswire/ -- Vital Access Corporation today announced the launch of the SAVE-2 post-market clinical follow-up study. The SAVE-2 study follows the U.S. SAVE study, an IDE pivotal trial that clearly demonstrated the benefits of the VWING(TM) Vascular Needle Guide in restoring vascular access to hemodialysis patients with uncannulatable and deep arteriovenous fistulae. This robust...

2013-09-26 16:26:06

AUSTIN, Texas, Sept. 26, 2013 /PRNewswire/ -- Preliminary data presented last week at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual scientific meeting demonstrated that TVA Medical's FLEX System can create vascular access for hemodialysis patients without traditional open surgery. The technology is being studied outside of the United States and is currently not available in the U.S. The Company intends to seek Food and Drug Administration...

2013-09-20 16:24:23

ORANGEBURG, S.C. and SALT LAKE CITY, Sept. 20, 2013 /PRNewswire/ -- Vital Access today announced the first U.S. commercial implantation of their VWING(TM) Vascular Needle Guide, in a patient presenting with cannulation challenges and with difficulties in achieving ideal dialysis access due to the depth and tortuosity of their AV fistula. The VWING Vascular Needle Guide was recently granted FDA market approval following completion of a multi-center, prospective clinical study....

2013-09-16 16:24:20

SALT LAKE CITY, Sept. 16, 2013 /PRNewswire/ -- Vital Access Corp. today announced that it has received U.S. Food and Drug Administration (FDA) market clearance for its patented VWING(TM) Vascular Needle Guide which has been shown to enable vascular access to arteriovenous fistulas (AVF) for patients undergoing hemodialysis. Kidney failure affects millions of people worldwide, and hemodialysis via an autologous arteriovenous fistula (AVF) is the global gold standard for patients...

2013-06-28 13:10:34

Study examines survival rates linked with different dialysis procedures to access the blood Elderly patients with kidney failure may not gain the same benefits from what's considered the gold standard for accessing the blood for dialysis compared with younger patients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). The findings suggest that vascular access procedures should be tailored to individual dialysis patients in the...

2013-06-10 20:21:42

AUSTIN, Texas, June 10, 2013 /PRNewswire/ -- TVA Medical, Inc. (TVA Medical), a medical device company developing minimally invasive therapies for End-Stage Renal Disease (ESRD), announced today that it received $9.5 MM in Series B financing. S3 Ventures led the round and was joined by TriStar Technology Ventures and existing investor, Santé Ventures. The funding will be used to further validate the Company's endovascular technology and complete additional clinical studies to...

2013-04-15 16:08:46

Abstract of the year: RENOVA trial results show stent grafts keep access sites open significantly longer than angioplasty alone Kidney failure patients on dialysis derive long-term benefit from the minimally invasive placement of a stent that improves the function of dialysis access grafts, according to 12-month trial results being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans. "Results of the study exceeded our expectations, and...